Media & Resources

New York, October 22, 2010 —The International AIDS Vaccine Initiative (IAVI) today announced the start of a Phase I clinical trial to evaluate the safety and immunogenicity of two preventive AIDS vaccine candidates. The trial, called B003/IPCAVD-004, is the first to test these vaccine candidates in a prime-boost combination, a regimen in which vaccines are given…

NEW YORK, September 27, 2010— A team of investigators headed by International AIDS Vaccine Initiative (IAVI) Investigator Pascal Poignard has been awarded a major grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the US National Institutes of Health (NIH) to investigate the biological mechanisms underlying the generation of broadly neutralizing antibodies by…

New York, August 10, 2010 — The International AIDS Vaccine Initiative (IAVI) is pleased to announce the appointment of Michael Caulfield as Executive Director of the IAVI AIDS Vaccine Design and Development Laboratory (DDL). Dr. Caulfield comes to IAVI from Merck, where he worked for 16 years, joining as a research fellow and rising to become…

New York, July 22, 2010—While celebrating news that a vaginal gel had for the first time demonstrated effectiveness at protecting women against HIV protection, health experts at the biannual International AIDS Conference this week in Vienna also trumpeted a new era in the effort to develop the long-sought AIDS vaccine. “There is a renaissance going…

VIENNA, 21 July, 2010 – Following significant advances in vaccine and microbicide research, importantly including results presented today of 39% efficacy in the CAPRISA 004 microbicide gel trial among women in South Africa, a new report released today warns that flat funding for HIV prevention research may limit researchers’ ability to quickly move promising approaches forward.…

New York, July 19, 2010— The International AIDS Vaccine Initiative (IAVI) is delighted by news that a clinical trial led by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) has provided the first evidence that a vaginal microbicide can provide women with protection from HIV infection. In the trial, named CAPRISA 004,…

IAVI Continues to Rank among Top One Percent of Charities Nationwide New York, July 14, 2010 — The International AIDS Vaccine Initiative (IAVI) has been awarded Charity Navigator’s four-star rating for the ninth year in a row—the organization’s highest ranking.  Charity Navigator, the nation’s largest independent charity evaluator, provides in-depth, objective ratings and analysis of the…

New York, July 6, 2010 — The International AIDS Vaccine Initiative (IAVI) announces the appointment of Margaret McGlynn, former President of Global Vaccines and Anti-infectives at Merck, to its board of directors. She joins a highly independent group of 16 advisors from 10 countries who meet three times a year to assess IAVI’s progress and shape…